Hosted on MSN3d
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
How Is The Market Feeling About Vertex Pharmaceuticals?
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Zacks.com on MSN4d
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
Vertex Pharmaceuticals: Strong Pipeline and Strategic Growth Propel ‘Buy’ Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Pharmaceuticals: Strong Future Potential with Key Drug Launches and Underappreciated Opportunities
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Wells Fargo & Company Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective cut by Wells Fargo & Company from $555.00 to ...
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Investing16d
Vertex stock rating downgraded at Raymond James
On Friday, Raymond (NS:RYMD) James altered its view on Vertex (NASDAQ:VRTX) Inc. (NASDAQ: VERX) stock, shifting from an "Outperform ... initiating coverage or upgrading their price targets for the ...